The stock of Protagonist Therapeutics Inc (PTGX) has seen a 2.90% increase in the past week, with a 12.99% gain in the past month, and a 52.36% flourish in the past quarter. The volatility ratio for the week is 2.84%, and the volatility levels for the past 30 days are at 4.41% for PTGX. The simple moving average for the last 20 days is 7.07% for PTGX stock, with a simple moving average of 48.08% for the last 200 days.
Is It Worth Investing in Protagonist Therapeutics Inc (NASDAQ: PTGX) Right Now?
The price-to-earnings ratio for Protagonist Therapeutics Inc (NASDAQ: PTGX) is above average at 16.33x. The 36-month beta value for PTGX is also noteworthy at 2.16. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PTGX is 55.64M, and at present, short sellers hold a 5.57% of that float. The average trading volume of PTGX on September 02, 2024 was 966.69K shares.
PTGX) stock’s latest price update
The stock price of Protagonist Therapeutics Inc (NASDAQ: PTGX) has surged by 1.42 when compared to previous closing price of 42.29, but the company has seen a 2.90% gain in its stock price over the last five trading sessions. zacks.com reported 2024-08-06 that Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago.
Analysts’ Opinion of PTGX
Many brokerage firms have already submitted their reports for PTGX stocks, with CapitalOne repeating the rating for PTGX by listing it as a “Overweight.” The predicted price for PTGX in the upcoming period, according to CapitalOne is $32 based on the research report published on October 30, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see PTGX reach a price target of $40, previously predicting the price at $30. The rating they have provided for PTGX stocks is “Buy” according to the report published on May 25th, 2023.
JMP Securities gave a rating of “Mkt Outperform” to PTGX, setting the target price at $21 in the report published on August 25th of the previous year.
PTGX Trading at 14.53% from the 50-Day Moving Average
After a stumble in the market that brought PTGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.99% of loss for the given period.
Volatility was left at 4.41%, however, over the last 30 days, the volatility rate increased by 2.84%, as shares surge +14.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.46% upper at present.
During the last 5 trading sessions, PTGX rose by +2.90%, which changed the moving average for the period of 200-days by +171.63% in comparison to the 20-day moving average, which settled at $40.33. In addition, Protagonist Therapeutics Inc saw 87.05% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTGX starting from Waddill William D., who sale 8,000 shares at the price of $40.00 back on Jul 24 ’24. After this action, Waddill William D. now owns 12,000 shares of Protagonist Therapeutics Inc, valued at $320,000 using the latest closing price.
Waddill William D., the Director of Protagonist Therapeutics Inc, sale 8,000 shares at $35.00 during a trade that took place back on Jun 07 ’24, which means that Waddill William D. is holding 12,000 shares at $280,000 based on the most recent closing price.
Stock Fundamentals for PTGX
Current profitability levels for the company are sitting at:
- 0.48 for the present operating margin
- 0.99 for the gross margin
The net margin for Protagonist Therapeutics Inc stands at 0.53. The total capital return value is set at 0.27. Equity return is now at value 40.69, with 36.35 for asset returns.
Based on Protagonist Therapeutics Inc (PTGX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 17.0. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 66.31.
Currently, EBITDA for the company is -90.34 million with net debt to EBITDA at -2.23. When we switch over and look at the enterprise to sales, we see a ratio of 6.84. The receivables turnover for the company is 232.93for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.73.
Conclusion
In summary, Protagonist Therapeutics Inc (PTGX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
